

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Kaysen
<b>Date of appointment</b>	5 November 2018

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Number &amp; class of Securities</b>
Nil	

+ See chapter 19 for defined terms.

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Mr Kaysen was appointed as Managing Director and Chief Executive Officer of the Company under an Executive Services Agreement. The terms of the agreement provide for Mr Kaysen is entitled to take part in the Company's Short-Term Incentive ("STI") and Long-Term Incentive ("LTI") programs.
<b>Nature of interest</b>	<p>The STI component will be 50% of base salary annual, payable in cash or shares (subject to shareholder approval) at Mr Kaysen's election. For the current year, ending 30 June 2019, the STI will be prorated based on start date and objectives will be agreed to by the Board in the first 30 days of employment.</p> <p>The LTI component will be the issue of 10 million \$0.45 options with a 5-year term, from the date of issue. Two million options will vest annually with Mr Kaysen's engagement over a period of 5 years.</p>
<b>Name of registered holder (if issued securities)</b>	Mr David Kaysen (or his nominee)
<b>No. and class of securities to which interest relates</b>	<p>The STI component the current year, ending 30 June 2019, the STI will be prorated based on start date and objectives will be agreed to by the Board in the first 30 days of employment.</p> <p>10,000,000 options exercisable at \$0.45 with a 5-year term, from the date of issue. Two million options will vest annually with Mr Kaysen's engagement over a period of 5 years.</p>

---

+ See chapter 19 for defined terms.